This IQVIA insight brief outlines how early-stage biotech firms can attract venture capital by de-risking development. Three tools are critical: a strategic Target Product Profile (TPP) to align vision and market needs, a Clinical Development Plan (CDP) to model timelines, costs, and risks, and expected Net Present Value (eNPV) to quantify asset value. Companies should refine TPPs with stakeholder input, use scenario modeling to weigh aggressive vs. conservative paths, and ground decisions in real-world data. Success comes from clear product positioning, robust forecasting, and data-driven trade-offs.

Join for free to read